GSEP
LGND icon

Golden State Equity Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Golden State Equity Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-54
Closed -$5.4K – 671
2024
Q3 		$5.4K Buy
+54
New +$5.44K ﹤0.01% 648

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Golden State Equity Partners's LGND Position: Q4 2024 in Review

Golden State Equity Partners sold out of Ligand Pharmaceuticals (LGND) in Q4 2024, closing a stake of 54 shares — an estimated $5.4K sold.

Golden State Equity Partners first reported a position in LGND in Q3 2024 and held it in 1 quarter. The position peaked at $5.4K in Q3 2024. 258 funds tracked by Wall St. Rank hold LGND as of Q4 2024.

  • Golden State Equity Partners reported no remaining Ligand Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Golden State Equity Partners sold 54 Ligand Pharmaceuticals shares in Q4 2024, an estimated $5.4K.
  • Golden State Equity Partners first reported a position in Ligand Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Golden State Equity Partners's Ligand Pharmaceuticals position peaked at $5.4K in Q3 2024.
  • 258 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2024.

Based on Golden State Equity Partners's 13F filing for Q4 2024, filed 24 Jan 2025.